Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clene Inc
(NQ:
CLNN
)
5.570
+0.060 (+1.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clene Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Clene: Q4 Earnings Insights
March 13, 2024
Via
Benzinga
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference
March 07, 2024
Via
Investor Brand Network
A Comparison Between ALS, Parkinson’s Disease
March 01, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum
February 29, 2024
Via
Investor Brand Network
Clene Inc. announces positive results from CNM-Au8 results from MS trial
February 05, 2024
--News Direct--
Via
News Direct
BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle
February 27, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data
February 22, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients
February 20, 2024
Via
Investor Brand Network
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 14, 2024
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 13, 2024
Via
Benzinga
Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)
February 13, 2024
Via
Investor Brand Network
7 Underappreciated Penny Stocks That Pack a Wallop
February 12, 2024
Although extreme speculation inherently attracts astounding risks, these underappreciated penny stocks could beat the odds.
Via
InvestorPlace
New MRI Procedure Eases Multiple Sclerosis Diagnosis
February 12, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview
February 06, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
February 06, 2024
Via
Investor Brand Network
Clene Inc. announces positive results from CNM-Au8 results from MS trial
February 05, 2024
Clene Inc (NASDAQ:CLNN) CEO Rob Etherington joined Steve Darling from Proactive to share news regarding the latest findings from the long-term open-label extension (LTE) of the VISIONARY-MS trial.
Via
TheNewswire.com
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients
February 02, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline
January 30, 2024
Via
Investor Brand Network
Researchers Propose New Way to Classify Parkinson’s Disease
January 29, 2024
Via
Investor Brand Network
Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment
January 24, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment
January 22, 2024
Via
Investor Brand Network
Ancient DNA Suggests Origins of Multiple Sclerosis in EU
January 17, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial
January 08, 2024
Via
Investor Brand Network
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
New Study Highlights Role of Mitochondria in Connecting Cancer to Dietary Fat
January 04, 2024
Via
Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Indicate CNM-Au8(R)’s Ability to Increase Key Brain Metabolites, Supporting Advancement to Phase 3 Trials
January 02, 2024
Via
Investor Brand Network
Finnish Study Suggests Exercise Plays Smaller Role in Longevity
December 21, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces New Data from HEALEY ALS Platform Trial, Provides Update on ALS Clinical Development Meeting with FDA
December 21, 2023
Via
Investor Brand Network
Exposures
Product Safety
Nasdaq Gains 100 Points; CarMax Earnings Top Views
December 21, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
FDA Refuses Neurology-Focused Clene's Accelerated Approval For Amyotrophic Lateral Sclerosis Treatment, Shares Fall
December 21, 2023
Clene Inc (NASDAQ: CLNN) provided an amyotrophic lateral sclerosis (ALS) regulatory update from its recent meeting with the FDA to discuss CNM-Au8 for ALS, presenting initial clinical and Neurofilament...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.